Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. Ca A Cancer J Clinicians. 2023 Jan;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Lovly CM. Expanding horizons for treatment of early-stage lung cancer. N Engl J Med. 2022 May;386(21):2050–2051. doi: 10.1056/NEJMe2203330
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. (London, England). 2019 May 4;393(10183):1819–1830. doi: 10.1016/s0140-6736(18)32409-7; (London, England).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019 Aug 1;30(8):1244–1253. doi: 10.1093/annonc/mdz175; PubMed PMID: 31143921; eng.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19): 1823–1833. doi: 10.1056/NEJMoa1606774; PubMed PMID: 27718847; eng.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017 Feb;17(2):97–111. doi: 10.1038/nri.2016.107; PubMed PMID: 27748397; eng.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on cell death 2018. Cell Death Differ. 2018 Mar;25(3):486–541. doi: 10.1038/s41418-017-0012-4; PubMed PMID: 27748397; eng.
   PubMed Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi: 10.3389/fimmu.2015.00588; PubMed PMID: 26635802; PubMed Central PMCID: PMCPMC4653610. eng.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med. 2007 Jan;13(1):54–61. doi: 10.1038/nm1523; PubMed PMID: 17187072; eng.
   PubMed Web of Science ®Google Scholar
• Krombach J, Hennel R, Brix N, et al. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8(1):e1523097. doi: 10.1080/2162402x.2018.1523097; PubMed PMID: 30546963; PubMed Central PMCID: PMCPMC6287777. eng.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Nikolos F, Lee YC, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020 Dec 7;11(1): 6299. doi: 10.1038/s41467-020-19970-9; PubMed PMID: 33288764; PubMed Central PMCID: PMCPMC7721802. eng.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Med. 2018 May;24(5):541–550. doi: 10.1038/s41591-018-0014-x; PubMed PMID: 29686425; PubMed Central PMCID: PMCPMC5998822. eng.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019 Sep 15;79(18):4557–4566. doi: 10.1158/0008-5472.Can-18-39620; PubMed PMID: 31350295; PubMed Central PMCID: PMCPMC6744958. eng.
   PubMed Web of Science ®Google Scholar
• Heymann MF, Lézot F, Heymann D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol. 2019 Sep;343:103711. doi: 10.1016/j.cellimm.2017.10.011; PubMed PMID: 29117898; eng.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nature Biotechnol. 2020 Jun;38(6):675–678. doi: 10.1038/s41587-020-0546-8; PubMed PMID: 32444850; PubMed Central PMCID: PMCPMC7386072. eng.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 26(12): (Oxford, England). 1572–1573. 2010 Jun 15. doi: 10.1093/bioinformatics/btq170; PubMed PMID: 20427518; PubMed Central PMCID: PMCPMC2881355. eng.
   PubMed Web of Science ®Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013 Dec 30;32(30):5381–97. doi: 10.1002/sim.5958; PubMed PMID: 24027076; eng.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Medical Decis Mak. 2006 Nov-Dec;26(6):565–574. doi: 10.1177/0272989x06295361; PubMed PMID: 17099194; PubMed Central PMCID: PMCPMC2577036. eng.
   PubMed Web of Science ®Google Scholar
• Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016 Feb;5(2):e1069938. doi: 10.1080/2162402x.2015.1069938; PubMed PMID: 27057433; PubMed Central PMCID: PMCPMC4801472. eng.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Vitale I, Harrington KJ, et al. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020 Feb;21(2):120–134. doi: 10.1038/s41590-019-0561-4; PubMed PMID: 31873291; eng.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Anderson R. Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy. Int J Mol Sci. 2019 Feb 22;20(4). doi: 10.3390/ijms20040959; PubMed PMID: 30813267; PubMed Central PMCID: PMCPMC6412296. eng.
   Web of Science ®Google Scholar
• Li X. The inducers of immunogenic cell death for tumor immunotherapy. Tumori. 2018 Jan-Feb;104(1):1–8. doi: 10.5301/tj.5000675; PubMed PMID: 28967094; eng.
   PubMed Web of Science ®Google Scholar
• Radogna F, Diederich M. Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochem Pharmacol. 2018 Jul;153:12–23. doi: 10.1016/j.bcp.2018.02.006; PubMed PMID: 29438676; eng.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019 Aug;23(8):4854–4865. doi: 10.1111/jcmm.14356; PubMed PMID: 31210425; PubMed Central PMCID: PMCPMC6653385. eng.
   PubMed Web of Science ®Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017 Nov;280(1):126–148. doi: 10.1111/imr.12574; PubMed PMID: 29027218; eng.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhong X, Cui H, et al. Identification of an individualized prognostic signature based on the RWSR model in early-stage bladder carcinoma. Bio Med Res Int. 2020;2020:9186546. doi: 10.1155/2020/9186546; PubMed PMID: 32596394; PubMed Central PMCID: PMCPMC7293744. eng.
   Google Scholar
• Feng Y, Xiong X, Wang Y, et al. Genomic analysis reveals the prognostic and Immunotherapeutic response characteristics of ferroptosis in lung squamous cell carcinoma. Lung. 2022 Jun;200(3):381–392. doi: 10.1007/s00408-022-00537-y; PubMed PMID: 35511293; eng.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Liu H, Zhou X, et al. Necroptosis-related lncRnas: predicting prognosis and the distinction between the cold and hot tumors in gastric cancer. J Oncol. 2021;2021:1–16. doi: 10.1155/2021/6718443; PubMed PMID: 34790235; PubMed Central PMCID: PMCPMC8592775 publication of this study. eng.
   Web of Science ®Google Scholar
• Ye Y, Dai Q, Qi H. A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer. Cell Death Discov. 2021 Apr 7;7(1):71. doi: 10.1038/s41420-021-00451-x; PubMed PMID: 33828074; PubMed Central PMCID: PMCPMC8026591. eng.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal For Immuno Therapy Of Cancer. 2020 Mar;8(1): doi: 10.1136/jitc-2019-000337; PubMed PMID: 32209603; PubMed Central PMCID: PMCPMC7064135. eng.
   Web of Science ®Google Scholar
• Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Scis. 2014 Mar;13(3):474–487. doi: 10.1039/c3pp50333j; PubMed PMID: 24493131; eng.
   PubMed Web of Science ®Google Scholar
• Huang X, Tang T, Zhang G, et al. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021 Mar 8;20(1):50. doi: 10.1186/s12943-021-01342-6; PubMed PMID: 33685460; PubMed Central PMCID: PMCPMC7938044. eng.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005 Oct 25;102(43): 15545–50. 10.1073/pnas.0506580102; PubMed PMID: 16199517; PubMed Central PMCID: PMCPMC1239896. eng.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen Y, Gao W, et al. Identification and validation of a four-gene ferroptosis signature for predicting overall survival of lung squamous cell carcinoma. Front Oncol. 2022;12:933925. doi: 10.3389/fonc.2022.933925
   PubMedGoogle Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612; PubMed PMID: 24113773; PubMed Central PMCID: PMCPMC3826632. eng.
   PubMed Web of Science ®Google Scholar
• Qian H, Lei T, Hu Y, et al. Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis in osteosarcoma. Front Cell Dev Biol. 2021;9:673827. doi: 10.3389/fcell.2021.673827
   PubMed Web of Science ®Google Scholar
• Feng H, Zhao Y, Yan W, et al. Identification of signature genes and characterizations of tumor immune microenvironment and tumor purity in lung adenocarcinoma based on machine learning. Front Med (Lausanne). 2022;9:843749. doi: 10.3389/fmed.2022.843749; PubMed PMID: 35280857; PubMed Central PMCID: PMCPMC8916235. eng.
   PubMed Web of Science ®Google Scholar
• Li N, Li Y, Zheng P, et al. Cancer Stemness-Based Prognostic Immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma. Front Endocrinol (Lausanne). 2021;12:755805. doi: 10.3389/fendo.2021.755805; PubMed PMID: 34745015; PubMed Central PMCID: PMCPMC8567176. eng.
   PubMed Web of Science ®Google Scholar
• Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017 Apr 11;16(1):76. doi: 10.1186/s12943-017-0646-3; PubMed PMID: 28399876; PubMed Central PMCID: PMCPMC5387196. eng.
   PubMedGoogle Scholar
• Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One. 2008 Mar 5;3(3): e0001722. 10.1371/journal.pone.0001722; PubMed PMID: 18320023; PubMed Central PMCID: PMCPMC2254495. eng.
   PubMed Web of Science ®Google Scholar
• Patel K, Wen J, Magliocca K, et al. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother Pharmacol. 2014 Nov;74(5):1015–1022. doi: 10.1007/s00280-014-2584-8; PubMed PMID: 25205430; eng.
   PubMed Web of Science ®Google Scholar
• Huang T, Chen S, Han H, et al. Expression of Hsp90α and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation. Int J Clin Exp Pathol. 2014;7(4):1544–52. PubMed PMID: 24817950; PubMed Central PMCID: PMCPMC4014234. eng.
   PubMed Web of Science ®Google Scholar
• McCarthy MM, Pick E, Kluger Y, et al. HSP90 as a marker of progression in melanoma. Ann Oncol. 2008 Mar;19(3):590–4. doi: 10.1093/annonc/mdm545; PubMed PMID: 18037622; eng.
   PubMed Web of Science ®Google Scholar
• Alberti G, Vergilio G, Paladino L, et al. The chaperone system in breast cancer: roles and therapeutic prospects of the molecular chaperones Hsp27, Hsp60, Hsp70, and Hsp90. Int J Mol Sci. 2022 Jul;23(14):7792.
   PubMed Web of Science ®Google Scholar
• Zavareh RB, Spangenberg SH, Woods A, et al. HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins. Cell Chem Biol. 2021 Feb;28(2):158–168.e5.
   PubMed Web of Science ®Google Scholar
• Zhou C, Yu T, Zhu R, et al. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation. Int J Biol Sci. 2023 Feb;19(5):1471–1489.
   PubMed Web of Science ®Google Scholar
• Rao A, Taylor JL, Chi-Sabins N, et al. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res. 2012 Jul;72(13):3196–206.
   PubMed Web of Science ®Google Scholar
• Mbofung RM, McKenzie JA, Malu S, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 Sep;8(1):451. doi: 10.1038/s41467-017-00449-z
   PubMedGoogle Scholar
• Rahmy S, Mishra SJ, Murphy S, et al. Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Front Immunol. 2022 Oct;13:1005045.
   PubMed Web of Science ®Google Scholar
• Ge F, Wang Y, Sharma A, et al. Cytokine-induced killer cells in combination with heat shock protein 90 inhibitors functioning via the fas/fasL axis provides rationale for a potential clinical benefit in burkitt’s lymphoma. Int J Mol Sci. 2023 Aug;24(15):12476.
   PubMed Web of Science ®Google Scholar
• Xie M, Yu T, Jing X, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. Mol Cancer. 2020 Jun;19(1):112. doi: 10.1186/s12943-020-01208-3
   PubMed Web of Science ®Google Scholar
• Liu Z, Wei L, You G, et al. Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme. Open Med (Wars). 2023 Jun;18(1):20230716. doi: 10.1515/med-2023-0716
   PubMedGoogle Scholar
• Liao Y, Wang Y, Cheng M, et al. Weighted gene coexpression network analysis of features that control cancer stem cells reveals prognostic biomarkers in lung adenocarcinoma. Front Genet. 2020 Apr;11:311.
   PubMed Web of Science ®Google Scholar
• Liao Y, He D, Wen F. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy. Immunogenetics. 2021 Oct;73(5):369–380. doi: 10.1007/s00251-021-01223-8
   PubMed Web of Science ®Google Scholar